Oncopeptides AB (publ) (ONPPF)
ONPPF Stock Price Chart
Explore Oncopeptides AB (publ) interactive price chart. Choose custom timeframes to analyze ONPPF price movements and trends.
ONPPF Company Profile
Discover essential business fundamentals and corporate details for Oncopeptides AB (publ) (ONPPF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
16 Dec 2020
Employees
80.00
Website
https://www.oncopeptides.com/svCEO
Sofia Heigis
Description
Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally. Its lead product candidate is melflufen, an anti-cancer peptide drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.
ONPPF Financial Timeline
Browse a chronological timeline of Oncopeptides AB (publ) corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Nov 2025
Earnings released on 21 Aug 2025
Earnings released on 15 May 2025
EPS came in at -$0.28 , while revenue for the quarter reached $13.27M .
Earnings released on 27 Feb 2025
EPS came in at -$0.04 , while revenue for the quarter reached $892.26K , missing expectations by -17.38%.
Earnings released on 7 Nov 2024
EPS came in at -$0.04 , while revenue for the quarter reached $819.93K , missing expectations by -40.24%.
Earnings released on 14 Aug 2024
EPS came in at -$0.05 , while revenue for the quarter reached $771.55K , beating expectations by +17.38%.
Earnings released on 30 May 2024
EPS came in at -$0.05 , while revenue for the quarter reached $467.64K .
Stock split effective on 3 May 2024
Shares were split 1403 : 1000 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 27 Feb 2024
EPS came in at -$0.09 falling short of the estimated -$0.07 by -29.15%, while revenue for the quarter reached $527.90K , missing expectations by -81.53%.
Earnings released on 30 Sept 2023
EPS came in at -$0.04 surpassing the estimated -$0.06 by +34.78%, while revenue for the quarter reached $254.63K , missing expectations by -89.80%.
Earnings released on 30 Jun 2023
EPS came in at -$0.06 surpassing the estimated -$0.06 by +8.07%, while revenue for the quarter reached $2.39M , beating expectations by +2.52%.
Earnings released on 31 Mar 2023
EPS came in at -$0.08 falling short of the estimated -$0.06 by -18.80%, while revenue for the quarter reached $108.00K , missing expectations by -95.25%.
Earnings released on 16 Feb 2023
EPS came in at -$0.10 falling short of the estimated -$0.06 by -78.54%, while revenue for the quarter reached $54.68K , missing expectations by -97.23%.
Earnings released on 9 Nov 2022
EPS came in at -$1.00 falling short of the estimated -$0.72 by -38.89%, while revenue for the quarter reached -$85.50K , missing expectations by -147.66%.
Earnings released on 11 Aug 2022
EPS came in at -$0.79 surpassing the estimated -$0.87 by +9.20%, while revenue for the quarter reached $850.83K .
Earnings released on 4 May 2022
EPS came in at -$1.31 surpassing the estimated -$2.15 by +39.07%.
Earnings released on 17 Feb 2022
EPS came in at -$5.23 falling short of the estimated -$3.10 by -68.71%, while revenue for the quarter reached -$2.39M , missing expectations by -207.11%.
Earnings released on 24 Nov 2021
EPS came in at -$10.33 falling short of the estimated -$4.49 by -130.07%, while revenue for the quarter reached $6.18M .
Earnings released on 19 Aug 2021
EPS came in at -$0.32 surpassing the estimated -$4.85 by +93.40%, while revenue for the quarter reached $7.74M .
Earnings released on 26 May 2021
EPS came in at -$3.45 surpassing the estimated -$6.62 by +47.89%, while revenue for the quarter reached $2.21M .
Earnings released on 18 Feb 2021
EPS came in at -$7.59 falling short of the estimated -$6.22 by -22.03%.
Earnings released on 19 Nov 2020
EPS came in at -$5.71 surpassing the estimated -$6.06 by +5.78%.
ONPPF Stock Performance
Access detailed ONPPF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.